OSU-6162

OSU-6162 (PNU-96391), hem dopamin D2 reseptörlerinde hem de 5-HT2A reseptörlerinde kısmi bir agonist olarak hareket eden bir bileşiktir. Yakından ilişkili ilaç olan pridopidine benzer şekilde bir dopamin dengeleyici görevi görür ve hayvan çalışmalarında antipsikotik, anti-bağımlılık ve anti-Parkinson etkileri vardır.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]^[11]^[12]^[13]^[14]

Kaynakça

^ "(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease". NeuroReport. 8 (11): 2567-70. July 1997. doi:10.1097/00001756-199707280-00029. PMID 9261828.
^ "Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity". Synapse. 28 (4): 280-7. April 1998. doi:10.1002/(SICI)1098-2396(199804)28:4<280::AID-SYN3>3.0.CO;2-5. PMID 9517836. KB1 bakım: göster-yazarlar (link)
^ "Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease". Neurology. 53 (7): 1605-6. October 1999. doi:10.1212/wnl.53.7.1605. PMID 10534281.
^ "PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease". Neuropharmacology. 43 (5): 817-24. October 2002. doi:10.1016/s0028-3908(02)00144-2. PMID 12384167.
^ "Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis". Current Drug Targets. CNS and Neurological Disorders. 1 (2): 141-7. April 2002. doi:10.2174/1568007024606195. PMID 12769623.
^ "The substituted (S)-3-phenylpiperidine (-)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys". Journal of Neural Transmission. 113 (1): 11-9. January 2006. doi:10.1007/s00702-005-0297-1. PMID 15795789.
^ "The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 29 (5): 833-9. June 2005. doi:10.1016/j.pnpbp.2005.03.003. PMID 15913873.
^ "The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat". The Journal of Pharmacology and Experimental Therapeutics. 318 (2): 810-8. August 2006. doi:10.1124/jpet.106.102905. PMID 16648369.
^ "Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis". European Journal of Pharmacology. 557 (2–3): 151-3. February 2007. doi:10.1016/j.ejphar.2006.11.016. PMID 17157291.
^ "Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D2 receptor function in vitro". Journal of Neural Transmission. 114 (9): 1143-6. September 2007. doi:10.1007/s00702-007-0784-7. PMID 17612788.
^ "Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization". Journal of Neural Transmission. 115 (6): 899-908. June 2008. doi:10.1007/s00702-008-0038-3. PMID 18351286.
^ "Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion". European Neuropsychopharmacology. 19 (6): 416-30. June 2009. doi:10.1016/j.euroneuro.2009.01.014. PMID 19269794.
^ "The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties". European Journal of Pharmacology. 628 (1–3): 19-26. February 2010. doi:10.1016/j.ejphar.2009.11.025. PMID 19919834. KB1 bakım: göster-yazarlar (link)
^ "Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor". British Journal of Pharmacology. 161 (6): 1343-50. November 2010. doi:10.1111/j.1476-5381.2010.01010.x. PMC 3000658 . PMID 20804495.

[1] "(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease". NeuroReport. 8 (11): 2567-70. July 1997. doi:10.1097/00001756-199707280-00029. PMID 9261828.

[2] "Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity". Synapse. 28 (4): 280-7. April 1998. doi:10.1002/(SICI)1098-2396(199804)28:4<280::AID-SYN3>3.0.CO;2-5. PMID 9517836. KB1 bakım: göster-yazarlar (link)

[3] "Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease". Neurology. 53 (7): 1605-6. October 1999. doi:10.1212/wnl.53.7.1605. PMID 10534281.

[4] "PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease". Neuropharmacology. 43 (5): 817-24. October 2002. doi:10.1016/s0028-3908(02)00144-2. PMID 12384167.

[5] "Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis". Current Drug Targets. CNS and Neurological Disorders. 1 (2): 141-7. April 2002. doi:10.2174/1568007024606195. PMID 12769623.

[6] "The substituted (S)-3-phenylpiperidine (-)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys". Journal of Neural Transmission. 113 (1): 11-9. January 2006. doi:10.1007/s00702-005-0297-1. PMID 15795789.

[7] "The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 29 (5): 833-9. June 2005. doi:10.1016/j.pnpbp.2005.03.003. PMID 15913873.

[8] "The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat". The Journal of Pharmacology and Experimental Therapeutics. 318 (2): 810-8. August 2006. doi:10.1124/jpet.106.102905. PMID 16648369.

[9] "Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis". European Journal of Pharmacology. 557 (2–3): 151-3. February 2007. doi:10.1016/j.ejphar.2006.11.016. PMID 17157291.

[10] "Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D2 receptor function in vitro". Journal of Neural Transmission. 114 (9): 1143-6. September 2007. doi:10.1007/s00702-007-0784-7. PMID 17612788.

[11] "Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization". Journal of Neural Transmission. 115 (6): 899-908. June 2008. doi:10.1007/s00702-008-0038-3. PMID 18351286.

[12] "Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion". European Neuropsychopharmacology. 19 (6): 416-30. June 2009. doi:10.1016/j.euroneuro.2009.01.014. PMID 19269794.

[13] "The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties". European Journal of Pharmacology. 628 (1–3): 19-26. February 2010. doi:10.1016/j.ejphar.2009.11.025. PMID 19919834. KB1 bakım: göster-yazarlar (link)

[14] "Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor". British Journal of Pharmacology. 161 (6): 1343-50. November 2010. doi:10.1111/j.1476-5381.2010.01010.x. PMC 3000658 . PMID 20804495.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]